EAU25 Press release: Twice as many men recover erectile function after improved prostate cancer surgery

The trial evaluated a method (called NeuroSAFE) of preserving the nerves that run through the prostate’s outer layers, which are thought to be responsible for producing erections, during prostate removal. The pioneering method includes an additional test to ensure that all of the cancerous cells are removed, so that preserving the nerves does not risk the surgery’s success.

In recent years, preservation of these nerves has been made possible by robotic surgery technology1 that gives the surgeon the precision required to peel off and retain the outermost layers of the prostate where the nerves are situated, a process known as ‘nerve-sparing’.

However, during standard surgery, it can be difficult to determine whether retaining these outer layers risks leaving some cancerous cells behind. In many cases, especially where the tumour is most advanced, surgeons will err on the side of caution and forego nerve-sparing to ensure that all of the patient’s cancer is removed.

NeuroSAFE enables them to check during the operation whether further tissue removal is needed or not.

Professor Greg Shaw, the trial lead from UCL Surgery & Interventional Science and Consultant Urologist at UCLH, said: “Our results show that, by using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery. It is an involved procedure that requires expertise, but it isn’t expensive, particularly given the benefits it offers for patients, and most importantly doesn’t jeopardise cancer control.

“NeuroSAFE wouldn’t be appropriate for all patients, as many can safely have nerve-sparing surgery using standard robotic techniques. But for younger patients and those who wouldn’t normally be seen as eligible for nerve-sparing surgery, it offers them a greater chance to hold onto their quality of life.”

The NeuroSAFE PROOF trial, run across five UK hospitals2, is the first randomised, controlled trial to fully evaluate the impact of the NeuroSAFE technique on erectile dysfunction and urinary incontinence – two of the most common side effects of prostate surgery.

The trial analysed outcomes for 344 men diagnosed with prostate cancer who were due to undergo prostate removal and who had no prior issues with erectile dysfunction. Half were randomised to receive NeuroSAFE during their operation and half had standard surgery.

Twelve months after surgery, 39% of men in the NeuroSAFE arm had no or mild erectile dysfunction3. In those men who had standard surgery, this was 23%.

A year after their operation, only 38% of those who had surgery using NeuroSAFE had severe erectile dysfunction, compared to 56% of men who had standard surgery.

The technique did not increase the overall proportion of patients who eventually returned to being fully continent at 12 months. However, NeuroSAFE patients who recovered their urinary control did so faster than patients who underwent standard surgery.

In the NeuroSAFE technique, which has been available for over a decade but is not widely used outside of Germany where it was invented, the surgeon extracts the prostate gland while preserving the maximum amount of nerve tissue around it as possible. The prostate is then flash-frozen and samples of it are examined by a pathologist while the operation is still underway. If cancer is found at the edges of the prostate, around where key nerves are situated, the surgeon can then remove additional tissue, sacrificing the nerves but achieving a complete removal of the tumour. If no cancer is found the operation is complete.

This additional step to rapidly examine the prostate means that more patients are able to benefit from nerve sparing, while still ensuring that all of the cancer will be removed.

Dr Ricardo Almeida-Magana, lead author on the Lancet Oncology paper from UCL Surgery & Interventional Science, said: “NeuroSAFE offers surgeons a real-time evaluation of the safety of the procedure. In standard robotic surgery, surgeons determine whether to choose nerve-sparing based on MRI scans, digital rectal examinations and biopsy results before surgery.

“But whereas those methods can provide guidance, NeuroSAFE provides certainty. And that opens up the option of nerve-sparing surgery for many more men, without compromising on the chances of controlling the cancer.”

Derya Tilki, a member of the EAU Scientific Congress Office and Professor of Urology at the Martini Klinik Prostate Cancer Center in Hamburg, Germany, where the NeuroSAFE technique was developed, said: “We use NeuroSAFE for most of the 2,500 prostate cancer patients we treat each year and it’s great to see the technique assessed in a randomised controlled trial for the first time. The results are as we would expect: NeuroSAFE allows more patients to have nerve sparing and that results in better recovery of erectile function. Post-surgical penile rehabilitation for patients can affect erectile function as well, so that is an aspect that also needs to be considered.

“This trial wasn’t designed to look at longer-term cancer outcomes but based on the data we have from using the technique for over 20 years, NeuroSAFE does not appear to affect these. It would be really valuable to have that confirmed in another randomised trial.”

The study was funded by the National Institute for Health and Care Research, The Rosetrees Foundation, St Peter’s Charitable Trust and the Jon Moulton Charity Trust.

Notes to editors

1 The surgeon operates a four-armed robot via a camera feed and controls, allowing them to make very precise and controlled incisions that wouldn’t be possible by hand. More information about the procedure is available on the Cancer Research UK website.

2 The hospitals involved in the trial were: University College London Hospitals NHS Foundation Trust, North Bristol Hospitals NHS Trust, Nottingham University Hospital NHS Trust, Sheffield Teaching Hospitals NHS Trust, and Greater Glasgow and Clyde NHS Trust.

3 Erectile dysfunction is commonly assessed using the International Index of Erectile Function (IIEF). This uses a 30-point scale based on responses to a questionnaire, where 30 is the highest score (no erectile difficulties).

Severe erectile dysfunction (IIEF score of 1-7) refers to the persistent inability to achieve or maintain an erection firm enough for satisfactory sexual performance, with little to no ability to get an erection under any circumstances, including during arousal or upon waking.

Mild to no erectile dysfunction equates to an IIEF score of 17-25.

The authors would like to acknowledge the support of surgical teams across all participating sites. We are particularly grateful to the UCLH robotic urology team consisting of Justin Collins, Nicolo De Luyk, Anand Kelkar, Senthil Nathan, Prash Patel, Prabs Rajan, Prasanna Sooriakumaran, and Ashwin Sridhar.

Contacts

For more information, please contact:
Dr Matt Midgley
+44 (0)20 7679 9064
m.midgley@ucl.ac.uk

Sharon Spiteri
+44 7930 610105
uclh.media@nhs.net

For interview requests at the EAU Congress, please contact:

Abi Chard / Dan Richards-Doran, Campus PR
+44 (0) 7960 448 532 / +44 (0) 7957 351 810
eaupress@campuspr.co.uk

Publication:
Dineen E and Almeida-Magana R et al. ‘Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial’ will be published in The Lancet Oncology and is strictly embargoed until Monday 24 March 2025 at 09:00 GMT / 10:00 CET / 05:00 ET.

NeuroSAFE versus standard, robot-assisted radical prostatectomy (NeuroSAFE PROOF): a randomised, controlled, patient-blinded, IDEAL stage three trial by Almeida-Magana R, Dinneen E, Al-Hammouri T, Leurent B, Pan S, Haider A, Freeman A, Roberts N, Brew-Graves C, Clow R, William N, Aning J, Walton T, Persad R, Oakley N, Ahmad I, Dutto L, Briggs T, Allen C, Tandogdu Z, Adshead J, Oxley J, Kelly J, Shaw G will be presented at the 2025 EAU Congress on Monday 24 March 2025.

About UCL – London’s Global University

UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to explore new possibilities.

Since 1826, we have championed independent thought by attracting and nurturing the world’s best minds. Our community of more than 50,000 students from 150 countries and over 16,000 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.

The Times and Sunday Times University of the Year 2024, we are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.

We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.

For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.

We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.

www.ucl.ac.uk | Follow @uclnewson Bluesky | Read news at www.ucl.ac.uk/news/ | Listen to UCL podcasts on SoundCloud | View images on Flickr | Find out what’s on at UCL Minds

About UCLH
UCLH (University College London Hospitals NHS Foundation Trust) provides first-class acute and specialist services in six hospitals in Central London. UCLH is committed to education and research and forms part of UCLPartners which in March 2009 was officially designated as one of the UK’s first academic health science centres by the Department of Health. UCLH works closely with UCL, translating research into treatments for patients. Our cancer research is led and delivered by first-class teams across UCLH in clinical and research infrastructure and facilities which benefit from underlying support from the National Institute for Health and Care Research (NIHR). For more information visit www.uclh.nhs.uk. We are also on Facebook (UCLHNHS), Twitter (@uclh), Youtube (UCLHvideo) and Instagram (@uclh).

About EAU25
Europe’s biggest urology congress will take place from 21-24 March 2025 in Madrid, Spain. With over 1,700 abstracts presented and moderated live, the 40th Annual Congress of the European Association of Urology (EAU25) will be amongst Europe’s biggest medical congresses in 2025. The packed four-day scientific programme includes live surgery, state-of-the-art lectures, case discussions and debates. See the full scientific programme on the congress website: eau25.org